Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: Analysis of the control arm of PATRICIA

Journal of Infectious Diseases

Volumn 210, Issue 4, 2014, Pages 517-534

  Castellsagué, Xavier ^a   Naud, Paulo ^b   Chow, Song Nan ^c   Wheeler, Cosette M ^d   Germar, Maria Julieta V ^e   Lehtinen, Matti ^f   Paavonen, Jorma ^g   Jaisamrarn, Unnop ^h   Garland, Suzanne M ^i,j,k   Salmerón, Jorge ^l   Apter, Dan ^m   Kitchener, Henry ⁿ   Teixeira, Julio C ^o   Skinner, S Rachel ^p,q   Limson, Genara ^r   Szarewski, Anne ^s   Romanowski, Barbara ^t   Aoki, Fred Y ^u   Schwarz, Tino F ^v   Poppe, Willy A J ^w   Bosch, F Xavier ^a,x   De Carvalho, Newton S ^y   Peters, Klaus ^z   Tjalma, Wiebren A A ^aa   Safaeian, Mahboobeh ^ab   Raillard, Alice ^ac   Descamps, Dominique ^ad   Struyf, Frank ^ad   Dubin, Gary ^ae   Rosillon, Dominique ^ad   Baril, Laurence ^ad   more..

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^f UNIVERSITY OF TAMPERE   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

^h CHULALONGKORN UNIVERSITY   (Thailand)

ⁱ ROYAL WOMEN'S HOSPITAL   (United States)

^j MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^m Vaestoliitto   (Finland)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

^o UNIVERSITY OF CAMPINAS   (Brazil)

^p UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^q UNIVERSITY OF SYDNEY   (Australia)

^r UNIVERSITY OF THE PHILIPPINES   (Philippines)

^s QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^t UNIVERSITY OF ALBERTA   (Canada)

^u UNIVERSITY OF MANITOBA   (Canada)

^v Stiftung Juliusspital   (Germany)

^w UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^x Network on Cooperative Cancer Research RTICC   (Spain)

^y FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^z Facharzt für Frauenheilkunde und Geburtshilfe   (Germany)

^aa ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^ab NATIONAL CANCER INSTITUTE   (United States)

^ac 4Clinics ^*  (France)

^ad GSK   (Belgium)

^ae GLAXOSMITHKLINE   (United States)

more..

Author keywords

Cervical abnormality; HPV; Infection; Naturally acquired antibodies; Risk reduction

Indexed keywords

HUMAN PAPILLOMAVIRUS TYPE 16 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 18 ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CANCER GRADING; FEMALE; HUMAN; INFECTION RISK; INNATE IMMUNITY; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RISK REDUCTION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DISEASE;

CERVICAL ABNORMALITY; HPV; INFECTION; NATURALLY ACQUIRED ANTIBODIES; RISK REDUCTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84905594748     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu139     Document Type: Article

References (35)

1. de Sanjosé S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional survey. Lancet Oncol 2010; 11: 1048-56.
2. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374: 1975-85.
3. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenicHPV types (PATRICIA): final analysis of a double- blind, randomised study in young women. Lancet 2009; 374: 301-14.
4. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
5. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1916-27.
6. Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-39.
7. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994; 86: 494-9.
8. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 1997; 4: 122-6.
9. Faust H, Jelen MM, Poljak M, Klavs I, Učakar V, Dillner J. Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. J Clin Virol 2013; 4: 336-41.
10. Porras C, Bennett C, Safaeian M, et al. Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis 2010; 10: 238.
11. Tong Y, Ermel A, TuW, Shew M, Brown DR. Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women. J Med Virol 2013; 85: 1786-93.
12. Kjellberg L, Wang Z, Wiklund F, et al. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol 1999; 80: 391-8.
13. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-9.
14. Geijersstam V, Kibur M, Wang Z, et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998; 177: 1710-4.
15. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13: 324-7.
16. Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 2005; 14: 283-8.
17. Olsson SE, Kjaer S, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009; 5: 696-704.
18. Palmroth J, Namujju P, Simen-Kapeu A, et al. Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. Scand J Infect Dis 2010; 42: 379-84.
19. Ho GYF, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186: 737-42.
20. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti- HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010; 102: 1653-62.
21. Wentzensen N, Rodriguez AC, Viscidi R, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste natural history study. J Infect Dis 2011; 204: 94-102.
22. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70.
23. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/ 18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double- blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.
24. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100-10.
25. van Doorn L-J, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006; 44: 3292-8.
26. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Human Vacc 2008; 4: 425-34.
27. Roset Bahmanyar E, Paavonen J, Salmerón J, et al. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol 2012; 127: 440-50.
28. Merikukka M, KaasilaM, Namujju PB, et al. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer 2011; 128: 1114-9.
29. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res 2013; 6: 1242-50.
30. Roteli-Martins C, Naud P, Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8: 390-7.
31. Coseo S, Porras C, Hildesheim A, et al.; for the Costa Rica HPV Vaccine Trial (CVT) Group. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. Sex Transm Dis 2010; 37: 706-10.
32. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174: 927-36.
33. Insinga RP, Perez G, Wheeler CM, et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev 2010; 19: 1585-94.
34. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009; 200: 166-71.
35. Safaeian M, Ghosh A, Porras C, et al. Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev 2012; 21: 1547-54.